Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in ...

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology (“ESMO”) by several companies. Other updates were also in focus. Among ...

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...

EXCLUSIVE: The Osbrink Agency, the Los Angeles-based boutique agency which represents actors in film, television, commercials ...

We recently published a list of Jim Cramer’s Must-Watch List: 10 Stocks to Look After. In this article, we are going to take ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...